FOLH1 and prostate cancer: In the last decade, RLT of prostate cancer with radiopharmaceuticals targeted at prostate-specific membrane antigen (PSMA) has gained increasing clinical acceptance and more recently, regulatory approval to treat advanced prostate cancer.